Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2023; 69(5): 61-65


V.M. Kornatskyi, N.O. Ryzhkova, O.M. Parkhomenko, O.M. Lomakovsky, A.M. Dorokhina, Yu.V. Kornatskyi, V.G. Levchenko, A.V. Romanovskyi

    SI National Scientific Center M.D. Strazhesko Institute of Cardiology of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine


Seasonal coronaviruses may serve as an informative model for determining the duration of protection against reinfection during future waves of coronavirus disease. Data from the literature suggest that ELISA kits designed to detect antibodies to SARS-CoV-2 may also be sensitive to seasonal coronaviruses. The aim of our work was to perform a retrospective study to determine the presence of IgG and IgM to coronaviruses in Ukraine before the COVID-19 pandemic. The study was conducted on the serum of 321 patients with various cardiorheumatologic profiles who were treated in a hospital during 2013-2018. The obtained data indicate the possibility of cross-immunity among coronaviruses since antibodies to this virus were present in 3.3% of patients with acute myocardial infarction, 5.9% with systemic rheumatological diseases, and 27.3% with chronic coronary heart disease.

Keywords: coronavirus; cardiovascular diseases; antibodies.


  1. Edridge A, Kaczorowska J, Hoste A, Bakker M, Klein M, Loens K, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020; 26: 1691-3. CrossRef PubMed
  2. Drosten C, Günther S, Preiser W, van der Werf S, Brodt H, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967-76. CrossRef PubMed
  3. Dyrdak R, Hodcroft EB, Wahlund M, Neher RA, Albert J. Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A retrospective study in Stockholm. Sweden. 2009-2020. J Clin Virol. 2021;136:104754. CrossRef PubMed PubMedCentral
  4. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020; 20(9): e238-44. CrossRef PubMed
  5. Wang R, Simoneau CR, Kulsuptrakul J, Bouhaddou M, Travisano KA, Hayashi JM, et al. Genetic screens identify host factors for SARS-CoV-2 and common cold coronaviruses. Cell. 2021;184:106-19. CrossRef PubMed PubMedCentral
  6. Guthmiller JJ, Wilson PC. Remembering seasonal coronaviruses. Antibodies against seasonal coronaviruses react with SARS-CoV-2. Science. 2020;370 (6522):1272-3. CrossRef PubMed
  7. Adams O, Andrée M, Rabl D, Ostermann PN, Schaal H, Lehnert E, et al. Humoral response to SARS-CoV-2 and seasonal coronaviruses in COVID-19 patients. J Med Virol. 2022; 94:1096-103. CrossRef PubMed PubMedCentral
  8. Ruetalo N, Businger R, Althaus K, Fink S, Ruoff F, Pogoda M, et al. Antibody response against SARS-CoV-2 and seasonal coronaviruses in nonhospitalized COVID-19 patients. mSphere. 2021; 6 (1):e01145-20. CrossRef PubMed PubMedCentral
  9. Kornatskyi VM, Ryzhkova NO, Gavrilenko TI, Dorokhina AM, Kornatsky YuVi, Pidgaina OA, Babii SM, Pasichnichenko OM. IgG, IgM and neutralizing antibodies to SARS-COV-2 in medical workers during the year (2020-2021) before the start of mass vaccination. Fiziol Zh. 2022; 68(3): 44-50. CrossRef
  10. Majdoubi A, Michalski C, O'Connell SE, Dada S, Narpala S, Gelinas J, et al. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2. JCI Insight. 2021; 6(8): e146316. CrossRef PubMed PubMedCentral
  11. Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S, et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat Commun. 2021;12: 4740. CrossRef PubMed PubMedCentral
  12. Wang G, Xiang Z, Wang W, Chen Z. Seasonal coronaviruses and SARS-CoV-2: Effects of preexisting immunity during the COVID-19 pandemic. J Zhejiang Univ-Sc (Biomed Biotech). 2022; 23(6):451-60. CrossRef PubMed PubMedCentral
  13. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-80. CrossRef PubMed PubMedCentral
  14. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020; 583 (7816):459-68. CrossRef PubMed PubMedCentral
  15. Daniels B, Sitapati M, Zhang J, Zou J, Bui QM, Ren J, et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Card. 2020; 136 (1):149-55. CrossRef PubMed PubMedCentral
  16. Andĕl M, Tsevegjav A, Roubalová K, Hrubá D, Dlouhý P, Kraml P. Infectious and inflammatory factors in the etiology and pathogenesis of atherosclerosis. Vnitr Lek. 2003 Dec;49(12):960-6.
  17. Li B, Xia Y, Hu B. Infection and atherosclerosis: TLR-dependent pathways. Cell Mol Life Sci. 2020 Jul;77(14):2751-69. CrossRef PubMed PubMedCentral

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.